{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-046340","form_type":"8-K","ticker":"DTIL","cik":"0001357874","company_name":"PRECISION BIOSCIENCES INC","filed_at":"2026-07-01T11:17:08+00:00","discovered_at":"2026-07-01T11:20:00.260609+00:00","generated_at":"2026-07-01T11:20:05.996133+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"PBGENE-HBV shows 1-log cccDNA reduction; DMD trial activates second site","bullets":["PBGENE-HBV in ELIMINATE-B study demonstrated 1-log (10-fold) reduction in cccDNA-derived transcripts from liver biopsy.","Company targets year-end 2026 for next program update on chronic hepatitis B.","FUNCTION-DMD trial for Duchenne muscular dystrophy activated second clinical site at Washington University in St. Louis.","Initial safety data from DMD trial targeted for year-end 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-046340","json":"https://secwatch.observer/filing/0001628280-26-046340.json","markdown":"https://secwatch.observer/filing/0001628280-26-046340.md","text":"https://secwatch.observer/filing/0001628280-26-046340.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1357874/000162828026046340/0001628280-26-046340-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1357874/000162828026046340/dtil-20260701.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-01T11:20:05.996133+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}